Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

444 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prolonged T-cell activation and long COVID symptoms independently associate with severe COVID-19 at 3 months.
Santopaolo M, Gregorova M, Hamilton F, Arnold D, Long A, Lacey A, Oliver E, Halliday A, Baum H, Hamilton K, Milligan R, Pearce O, Knezevic L, Morales Aza B, Milne A, Milodowski E, Jones E, Lazarus R, Goenka A, Finn A, Maskell N, Davidson AD, Gillespie K, Wooldridge L, Rivino L. Santopaolo M, et al. Among authors: lazarus r. Elife. 2023 Jun 13;12:e85009. doi: 10.7554/eLife.85009. Elife. 2023. PMID: 37310006 Free PMC article.
Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
Lazarus R, Querton B, Corbic Ramljak I, Dewasthaly S, Jaramillo JC, Dubischar K, Krammer M, Weisova P, Hochreiter R, Eder-Lingelbach S, Taucher C, Finn A; Valneva phase 3 trial group. Lazarus R, et al. Lancet Infect Dis. 2022 Dec;22(12):1716-1727. doi: 10.1016/S1473-3099(22)00502-3. Epub 2022 Sep 5. Lancet Infect Dis. 2022. PMID: 36075233 Free PMC article. Clinical Trial.
Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: A prospective test negative case-control study.
Chatzilena A, Hyams C, Challen R, Marlow R, King J, Adegbite D, Kinney J, Clout M, Maskell N, Oliver J, Danon L, Finn A; Avon CAP Research Group. Chatzilena A, et al. Lancet Reg Health Eur. 2022 Dec 7;25:100552. doi: 10.1016/j.lanepe.2022.100552. eCollection 2023 Feb. Lancet Reg Health Eur. 2022. PMID: 36506791 Free PMC article.
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C, Lazarus R, Dellago H, Maurer G, Weisova P, Corbic-Ramljak I, Dubischar K, Lilja A, Eder-Lingelbach S, Hochreiter R, Jaramillo JC, Junker H, Krammer M, Pusic P, Querton B, Larcher-Senn J, Hoffmann M, Pöhlmann S, Finn A; Valneva Phase 3 Booster Trial Group. Taucher C, et al. Among authors: lazarus r. J Infect. 2023 Sep;87(3):242-254. doi: 10.1016/j.jinf.2023.06.022. Epub 2023 Jul 3. J Infect. 2023. PMID: 37406777 Clinical Trial.
Delivering COVID-19 vaccine trials at speed: the implementation of a phase IV UK multi-centre randomised controlled trial to determine safety and immunogenicity of COVID-19 vaccines co-administered with seasonal influenza vaccines (ComFluCOV).
Baos S, Todd R, Thirard R, Harris R, Kirwan J, Joyce K, Hutton D, Finn A, Clout M, Cappel-Porter H, Rogers CA, Lazarus R, Culliford L. Baos S, et al. Among authors: lazarus r. Trials. 2024 Jan 11;25(1):39. doi: 10.1186/s13063-023-07862-4. Trials. 2024. PMID: 38212836 Free PMC article. Clinical Trial.
Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom.
Hyams C, Challen R, Marlow R, Nguyen J, Begier E, Southern J, King J, Morley A, Kinney J, Clout M, Oliver J, Gray S, Ellsbury G, Maskell N, Jodar L, Gessner B, McLaughlin J, Danon L, Finn A; AvonCAP Research Group. Hyams C, et al. Lancet Reg Health Eur. 2023 Feb;25:100556. doi: 10.1016/j.lanepe.2022.100556. Epub 2022 Dec 12. Lancet Reg Health Eur. 2023. PMID: 36530491 Free PMC article.
Association of ABO and Rhesus blood groups with severe outcomes from non-SARS-CoV-2 respiratory infection: A prospective observational cohort study in Bristol, UK 2020-2022.
Hathaway A, Qian G, King J, McGuinness S, Maskell N, Oliver J, Finn A, Danon L, Challen R, Toye AM, Hyams C; Avon CAP Research Group. Hathaway A, et al. Br J Haematol. 2024 Mar;204(3):826-838. doi: 10.1111/bjh.19234. Epub 2023 Nov 27. Br J Haematol. 2024. PMID: 38009561 Free PMC article.
Effect of second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare worker cohort.
Kirwan PD, Hall VJ, Foulkes S, Otter AD, Munro K, Sparkes D, Howells A, Platt N, Broad J, Crossman D, Norman C, Corrigan D, Jackson CH, Cole M, Brown CS, Atti A, Islam J; SIREN Study Group; Presanis AM, Charlett A, De Angelis D, Hopkins S. Kirwan PD, et al. Lancet Reg Health Eur. 2023 Dec 14;36:100809. doi: 10.1016/j.lanepe.2023.100809. eCollection 2024 Jan. Lancet Reg Health Eur. 2023. PMID: 38111727 Free PMC article.
444 results